Patompong Ungprasert1, Cynthia S Crowson1,2, Rodrigo Cartin-Ceba3, James A Garrity4, Wendy M Smith4, Ulrich Specks5, Eric L Matteson1,6, Ashima Makol1. 1. Division of Rheumatology, Department of Internal Medicine. 2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ. 4. Department of Ophthalmology. 5. Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine. 6. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Abstract
Objective: To characterize the clinical correlates and outcome of inflammatory ocular disease (IOD) among patients with ANCA-associated vasculitides (AAV). Methods: Medical records of potential cases of AAV seen at Mayo Clinic from 2003 to 2013, inclusive, were reviewed to identify confirmed cases meeting the diagnosis of AAV using the Chapel Hill Consensus Conference 2012 descriptors. Records of confirmed cases of AAV were then further reviewed for IOD, and clinical characteristics, treatment and outcomes abstracted. Results: A total of 1171 confirmed cases of AAV were identified of which 183 patients (mean age 49.0 years; 51% female; 95% Caucasian) had IOD. The most common manifestation of IOD was injection of the eye (57%) followed by eye pain (46%) and visual acuity loss (18%). Scleritis was the most common type of IOD (22%) followed by episcleritis (21%), orbital inflammation (18%), lacrimal duct stenosis (10%) and uveitis (9%). Oral glucocorticoids were used to treat IOD in the majority of patients (96%). CYC and rituximab were the most frequently used immunosuppressive agents (54 and 36%, respectively). Of those with orbital inflammation, 52% underwent therapeutic surgical intervention. Clinical remission of IOD was achieved in 91% of patients but relapses were seen in 23%. Significant visual acuity loss was observed in only six patients. Conclusion: IOD is a common manifestation of AAV and seen in about 16% of patients with AAV. Scleritis, episcleritis and orbital inflammation are the most common subtypes. Most patients respond well to glucocorticoids and immunosuppression, but relapse of IOD is common.
Objective: To characterize the clinical correlates and outcome of inflammatory ocular disease (IOD) among patients with ANCA-associated vasculitides (AAV). Methods: Medical records of potential cases of AAV seen at Mayo Clinic from 2003 to 2013, inclusive, were reviewed to identify confirmed cases meeting the diagnosis of AAV using the Chapel Hill Consensus Conference 2012 descriptors. Records of confirmed cases of AAV were then further reviewed for IOD, and clinical characteristics, treatment and outcomes abstracted. Results: A total of 1171 confirmed cases of AAV were identified of which 183 patients (mean age 49.0 years; 51% female; 95% Caucasian) had IOD. The most common manifestation of IOD was injection of the eye (57%) followed by eye pain (46%) and visual acuity loss (18%). Scleritis was the most common type of IOD (22%) followed by episcleritis (21%), orbital inflammation (18%), lacrimal duct stenosis (10%) and uveitis (9%). Oral glucocorticoids were used to treat IOD in the majority of patients (96%). CYC and rituximab were the most frequently used immunosuppressive agents (54 and 36%, respectively). Of those with orbital inflammation, 52% underwent therapeutic surgical intervention. Clinical remission of IOD was achieved in 91% of patients but relapses were seen in 23%. Significant visual acuity loss was observed in only six patients. Conclusion: IOD is a common manifestation of AAV and seen in about 16% of patients with AAV. Scleritis, episcleritis and orbital inflammation are the most common subtypes. Most patients respond well to glucocorticoids and immunosuppression, but relapse of IOD is common.
Authors: J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani Journal: Arthritis Rheum Date: 2001-04
Authors: Taewoo Lee; Adil Gasim; Vimal K Derebail; Yunro Chung; JulieAnne G McGregor; Sophia Lionaki; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Patrick H Nachman Journal: Clin J Am Soc Nephrol Date: 2014-02-27 Impact factor: 8.237
Authors: Martin Englund; Peter A Merkel; Gunnar Tomasson; Mårten Segelmark; Aladdin J Mohammad Journal: J Rheumatol Date: 2016-06-01 Impact factor: 4.666
Authors: J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts Journal: Arthritis Rheum Date: 2013-01
Authors: Min Joung Lee; Bronwyn E Hamilton; David Pettersson; Kimberly Ogle; Jennifer Murdock; Roger A Dailey; John D Ng; Eric A Steele; Rohan Verma; Stephen R Planck; Tammy M Martin; Dongseok Choi; James T Rosenbaum Journal: Sci Rep Date: 2020-12-14 Impact factor: 4.379
Authors: Carlos Cifuentes-González; Pilar Uribe-Reina; Juliana Reyes-Guanes; Juliana Muñoz-Ortiz; Paula Tatiana Muñoz-Vargas; William Rojas-Carabali; Dora Victoria Nova-Florián; Ana Sofía De-Los-Ríos; Rubén Dario Mantilla-Hernández; Alejandra de-la-Torre Journal: Clin Ophthalmol Date: 2022-08-09